Targeted therapy pralsetinib improves outcomes in RET fusion-positive NSCLCs
In some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth.
In some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth.